Latest Cannabinoids News

Page 7 of 7
Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.
Victor Sage
Victor Sage
28 Jan 2025
InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.
Ada Torres
Ada Torres
24 Jan 2025

Browse the archive

Full archive